Top

Journal of Autism and Developmental Disorders

15-12-2023 | Brief Report

Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder

Auteurs: Craig A. Erickson, Rebecca C. Shaffer, Meredith Will, Lauren M. Schmitt, Paul Horn, Kathy Hirst, Ernest V. Pedapati, Nicole Ober, Rameshwari V. Tumuluru, Benjamin L. Handen, David Q. Beversdorf

Gepubliceerd in: Journal of Autism and Developmental Disorders

Abstract

Neuroinflammatory mechanisms have been implicated in the pathophysiology of autism spectrum disorder (ASD). Minocycline is a matrix metalloproteinase inhibitor 9 (MMP9) inhibitor tetracycline antibiotic with known anti-inflammatory properties. In preclinical animal models of ASD, minocycline has demonstrated potential positive effects on phenotypes that may have relevance to ASD. We conducted the first placebo-controlled study of minocycline in ASD. This double-blind, placebo-controlled crossover trial employed four week treatment periods with a two week washout period. Twenty-four 12–22 year olds (mean age 17.4 years; range 12.9–22.5 years) with ASD were enrolled. Overall minocycline was well tolerated. No minocycline-associated clinical changes were noted with treatment on any performance or clinician or caregiver completed measures were noted. We hypothesize that either minocycline does not have potential therapeutic effects in ASD or our project was underpowered to define potential subject subgroups who may potentially respond positively to this drug.

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 5, 485–491.

Amoss, R. T., et al. (2020). A Pilot study of cardiovascular reactivity in children with autism spectrum disorder. Seminars in Pediatric Neurology, 34, 100807. https://doi.org/10.1016/j.spen.2020.100807CrossRefPubMed

Bortolanza, M., et al. (2018). Tetracycline repurposing in neurodegeneration: Focus on Parkinson’s disease. Journal of Neural Transmission (vienna), 125, 1403–1415. https://doi.org/10.1007/s00702-018-1913-1CrossRef

Buller, K. M., Carty, M. L., Reinebrant, H. E., & Wixey, J. A. (2009). Minocycline: A neuroprotective agent for hypoxic-ischemic brain injury in the neonate? Journal of Neuroscience Research, 87, 599–608. https://doi.org/10.1002/jnr.21890CrossRefPubMed

Carlezon, W. A., Jr., et al. (2019). Maternal and early postnatal immune activation produce sex-specific effects on autism-like behaviors and neuroimmune function in mice. Science and Reports, 9, 16928. https://doi.org/10.1038/s41598-019-53294-zCrossRef

Casamassimo, P. S., Shellhart, W. C., & Hagerman, R. (1986). Fragile X syndrome: A review. Journal of Oral Medicine, 41, 228–233.PubMed

Cheng, Y. C., Huang, Y. C., & Huang, W. L. (2020). Heart rate variability in individuals with autism spectrum disorders: A meta-analysis. Neuroscience and Biobehavioral Reviews, 118, 463–471. https://doi.org/10.1016/j.neubiorev.2020.08.007CrossRefPubMed

Dansie, L. E., et al. (2013). Long-lasting effects of minocycline on behavior in young but not adult fragile X mice. Neuroscience, 246, 186–198. https://doi.org/10.1016/j.neuroscience.2013.04.058CrossRefPubMed

Dziembowska, M., et al. (2013). High MMP-9 activity levels in fragile X syndrome are lowered by minocycline. American Journal of Medical Genetics. Part A, 161A, 1897–1903. https://doi.org/10.1002/ajmg.a.36023CrossRefPubMed

Elewa, H. F., Hilali, H., Hess, D. C., Machado, L. S., & Fagan, S. C. (2006). Minocycline for short-term neuroprotection. Pharmacotherapy, 26, 515–521. https://doi.org/10.1592/phco.26.4.515CrossRefPubMedCentralPubMed

Estes, M. L., & McAllister, A. K. (2015). Immune mediators in the brain and peripheral tissues in autism spectrum disorder. Nature Reviews Neuroscience, 16, 469–486. https://doi.org/10.1038/nrn3978CrossRefPubMedCentralPubMed

Ewen, J. B., Sweeney, J. A., & Potter, W. Z. (2019). Conceptual, regulatory and strategic imperatives in the early days of EEG-based biomarker validation for neurodevelopmental disabilities. Frontiers in Integrative Neuroscience, 13, 45–45. https://doi.org/10.3389/fnint.2019.00045CrossRefPubMedCentralPubMed

Frazier, T. W., Krishna, J., Klingemier, E., Beukemann, M., Nawabit, R., & Ibrahim, S. (2017). A randomized, crossover trial of a novel sound-to-sleep mattress technology in children with Autism and sleep difficulties. Journal of Clinical Sleep Medicine, 13, 95–104. https://doi.org/10.5664/jcsm.6398CrossRefPubMedCentralPubMed

Gesundheit, B., et al. (2013). Immunological and autoimmune considerations of Autism Spectrum Disorders. Journal of Autoimmunity, 44, 1–7. https://doi.org/10.1016/j.jaut.2013.05.005CrossRefPubMed

Guy, W. (1976). ECDEU assessment manual for psychopharmacology, Publication No. 76–338. Washington, DC: U.S. DHEW, NIMH.

Haigh, S. M., Walford, T. P., & Brosseau, P. (2021). Heart rate variability in Schizophrenia and Autism. Front Psychiatry, 12, 760396. https://doi.org/10.3389/fpsyt.2021.760396CrossRefPubMedCentralPubMed

Kaufmann, W. E., et al. (2017). Autism spectrum disorder in fragile X syndrome: Cooccurring conditions and current treatment. Pediatrics, 139, S194–S206. https://doi.org/10.1542/peds.2016-1159FCrossRefPubMedCentralPubMed

Koistinaho, J., Yrjanheikki, J., Kauppinen, T., & Koistinaho, M. (2004). Tetracycline derivatives as anti-inflammatory agents and potential agents in stroke treatment. Ernst Schering Research Foundation Workshop. https://doi.org/10.1007/978-3-662-05426-0_6CrossRefPubMed

Kumar, H., & Sharma, B. (2016). Minocycline ameliorates prenatal valproic acid induced autistic behaviour, biochemistry and blood brain barrier impairments in rats. Brain Research, 1630, 83–97. https://doi.org/10.1016/j.brainres.2015.10.052CrossRefPubMed

Leigh, M. J., et al. (2013). A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. Journal of Developmental and Behavioral Pediatrics, 34, 147–155. https://doi.org/10.1097/DBP.0b013e318287cd17CrossRefPubMedCentralPubMed

Lord, C., M. Rutter, P.C. DiLavore, S. Risi, K. Gotham, S. Bishop (2012). Autism diagnostic observation schedule: ADOS-2, Western Psychological Services Los Angeles, CA.

Lovelace, J. W., Ethell, I. M., Binder, D. K., & Razak, K. A. (2020). Minocycline treatment reverses sound evoked EEG abnormalities in a mouse model of fragile X syndrome. Frontiers in Neuroscience, 14, 771. https://doi.org/10.3389/fnins.2020.00771CrossRefPubMedCentralPubMed

Machado, L. S., Kozak, A., Ergul, A., Hess, D. C., Borlongan, C. V., & Fagan, S. C. (2006). Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neuroscience, 7, 56. https://doi.org/10.1186/1471-2202-7-56CrossRefPubMedCentralPubMed

Markowitz, L. A., Reyes, C., Embacher, R. A., Speer, L. L., Roizen, N., & Frazier, T. W. (2016). Development and psychometric evaluation of a psychosocial quality-of-life questionnaire for individuals with autism and related developmental disorders. Autism, 20, 832–844. https://doi.org/10.1177/1362361315611382CrossRefPubMed

McDougle, C. J., et al. (2015). Toward an immune-mediated subtype of autism spectrum disorder. Brain Research, 1617, 72–92. https://doi.org/10.1016/j.brainres.2014.09.048CrossRefPubMed

Miyazaki, S., Hiraoka, Y., Hidema, S., & Nishimori, K. (2016). Prenatal minocycline treatment alters synaptic protein expression, and rescues reduced mother call rate in oxytocin receptor-knockout mice. Biochemical and Biophysical Research Communications, 472, 319–323. https://doi.org/10.1016/j.bbrc.2016.02.109CrossRefPubMed

Morgan, J. T., et al. (2010). Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biological Psychiatry, 68, 368–376. https://doi.org/10.1016/j.biopsych.2010.05.024CrossRefPubMed

Pardo, C. A., et al. (2013). A pilot open-label trial of minocycline in patients with autism and regressive features. Journal of Neurodevelopmental Disorders, 5, 9. https://doi.org/10.1186/1866-1955-5-9CrossRefPubMedCentralPubMed

Paribello, C., et al. (2010). Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurology, 10, 91. https://doi.org/10.1186/1471-2377-10-91CrossRefPubMedCentralPubMed

Popovic, N., Schubart, A., Goetz, B. D., Zhang, S. C., Linington, C., & Duncan, I. D. (2002). Inhibition of autoimmune encephalomyelitis by a tetracycline. Annals of Neurology, 51, 215–223. https://doi.org/10.1002/ana.10092CrossRefPubMed

Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology, 20, 310–319. https://doi.org/10.1076/jcen.20.3.310.823CrossRefPubMed

Rodriguez, J. I., & Kern, J. K. (2011). Evidence of microglial activation in autism and its possible role in brain underconnectivity. Neuron Glia Biology, 7, 205–213. https://doi.org/10.1017/S1740925X12000142CrossRefPubMedCentralPubMed

Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M., & Razak, K. A. (2012). Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome. Brain Research, 1439, 7–14. https://doi.org/10.1016/j.brainres.2011.12.041CrossRefPubMed

Ryan, J. J., Kreiner, D. S., Teichner, G., & Gontkovsky, S. T. (2021). Validity of the Wechsler abbreviated scale ofqa intelligence, Second Edition (WASI-II) as an indicator of neurological disease/injury: A pilot study. Brain Injury., 35, 1624–1629.CrossRefPubMed

Sahin, M., et al. (2018). Discovering translational biomarkers in neurodevelopmental disorders Nat Rev Drug Discov. England.

Schneider, A., et al. (2013). Electrocortical changes associated with minocycline treatment in fragile X syndrome. Journal of Psychopharmacology, 27, 956–963. https://doi.org/10.1177/0269881113494105CrossRefPubMed

Schneider, T., & Przewlocki, R. (2005). Behavioral alterations in rats prenatally exposed to valproic acid: Animal model of autism. Neuropsychopharmacology, 30, 80–89. https://doi.org/10.1038/sj.npp.1300518CrossRefPubMed

Shigemori, T., Sakai, A., Takumi, T., Itoh, Y., & Suzuki, H. (2015). Altered Microglia in the Amygdala Are involved in anxiety-related behaviors of a copy number variation mouse model of Autism. Journal of Nippon Medical School, 82, 92–99. https://doi.org/10.1272/jnms.82.92CrossRefPubMed

Shultz, R. B., & Zhong, Y. (2017). Minocycline targets multiple secondary injury mechanisms in traumatic spinal cord injury. Neural Regeneration Research, 12, 702–713. https://doi.org/10.4103/1673-5374.206633CrossRefPubMedCentralPubMed

Siller, S. S., & Broadie, K. (2012). Matrix metalloproteinases and minocycline: Therapeutic avenues for fragile X syndrome. Neural Plasticity, 2012, 124548. https://doi.org/10.1155/2012/124548CrossRefPubMedCentralPubMed

Thapa, R., et al. (2021). Heart Rate variability in children with autism spectrum disorder and associations with medication and symptom severity. Autism Research, 14, 75–85. https://doi.org/10.1002/aur.2437CrossRefPubMed

Thom, R. P., et al. (2019). Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder. Psychopharmacology (berl), 236, 3045–3061. https://doi.org/10.1007/s00213-019-05280-6CrossRefPubMed

Tikka, T., Fiebich, B. L., Goldsteins, G., Keinanen, R., & Koistinaho, J. (2001). Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. Journal of Neuroscience, 21, 2580–2588.CrossRefPubMed

Toledo, M. A., Wen, T. H., Binder, D. K., Ethell, I. M., & Razak, K. A. (2019). Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9. Behavioural Brain Research, 372, 112068. https://doi.org/10.1016/j.bbr.2019.112068CrossRefPubMedCentralPubMed

Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology, 57, 67–81. https://doi.org/10.1002/ana.20315CrossRefPubMed

Wagner, G. C., Reuhl, K. R., Cheh, M., McRae, P., & Halladay, A. K. (2006). A new neurobehavioral model of autism in mice: Pre- and postnatal exposure to sodium valproate. Journal of Autism and Developmental Disorders, 36, 779–793. https://doi.org/10.1007/s10803-006-0117-yCrossRefPubMed

Yau, S. Y., et al. (2018). Chronic minocycline treatment improves hippocampal neuronal structure, NMDA receptor function, and memory processing in Fmr1 knockout mice. Neurobiology of Diseases, 113, 11–22. https://doi.org/10.1016/j.nbd.2018.01.014CrossRef

Yau, S. Y., Chiu, C., Vetrici, M., & Christie, B. R. (2016). Chronic minocycline treatment improves social recognition memory in adult male Fmr1 knockout mice. Behavioural Brain Research, 312, 77–83. https://doi.org/10.1016/j.bbr.2016.06.015CrossRefPubMed

Yoo, M. H., Kim, T. Y., Yoon, Y. H., & Koh, J. Y. (2016). Autism phenotypes in ZnT3 null mice: Involvement of zinc dyshomeostasis, MMP-9 activation and BDNF upregulation. Science and Reports, 6, 28548. https://doi.org/10.1038/srep28548CrossRef

Yu, T. W., & Berry-Kravis, E. (2014). Autism and fragile X syndrome. Seminars in Neurology, 34, 258–265. https://doi.org/10.1055/s-0034-1386764CrossRefPubMed

Zimmerman, A. W., et al. (2005). Cerebrospinal fluid and serum markers of inflammation in . Pediatric Neurology, 33, 195–201. https://doi.org/10.1016/j.pediatrneurol.2005.03.014CrossRefPubMed

Titel: Brief Report: A Double-Blind, Placebo-Controlled, Crossover, Proof-of-Concept Study of Minocycline in Autism Spectrum Disorder
Auteurs: Craig A. Erickson
Rebecca C. Shaffer
Meredith Will
Lauren M. Schmitt
Paul Horn
Kathy Hirst
Ernest V. Pedapati
Nicole Ober
Rameshwari V. Tumuluru
Benjamin L. Handen
David Q. Beversdorf
Publicatiedatum: 15-12-2023
Uitgeverij: Springer US
Gepubliceerd in: Journal of Autism and Developmental Disorders
Print ISSN: 0162-3257
Elektronisch ISSN: 1573-3432
DOI: https://doi.org/10.1007/s10803-023-06132-1

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Log in om toegang te krijgen